1721 related articles for article (PubMed ID: 31109652)
61. Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitis.
Wollenberg A; Beck LA; Blauvelt A; Simpson EL; Chen Z; Chen Q; Shumel B; Khokhar FA; Hultsch T; Rizova E; Rossi AB; Graham NMH; Pirozzi G; Lu Y; Ardeleanu M
Br J Dermatol; 2020 Jun; 182(6):e186-e209. PubMed ID: 32476149
[TBL] [Abstract][Full Text] [Related]
62. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
Deleuran M; Thaçi D; Beck LA; de Bruin-Weller M; Blauvelt A; Forman S; Bissonnette R; Reich K; Soong W; Hussain I; Foley P; Hide M; Bouaziz JD; Gelfand JM; Sher L; Schuttelaar MLA; Wang C; Chen Z; Akinlade B; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Staudinger H; Graham NMH; Pirozzi G; Ardeleanu M
J Am Acad Dermatol; 2020 Feb; 82(2):377-388. PubMed ID: 31374300
[TBL] [Abstract][Full Text] [Related]
63. Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment.
Armstrong A; Blauvelt A; Simpson EL; Smith CH; Herranz P; Kataoka Y; Seo SJ; Ferrucci SM; Chao J; Chen Z; Rossi AB; Shumel B; Tomondy P
Dermatol Ther (Heidelb); 2022 Jan; 12(1):195-202. PubMed ID: 34897582
[TBL] [Abstract][Full Text] [Related]
64. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
[TBL] [Abstract][Full Text] [Related]
65. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials.
Simpson EL; Merola JF; Silverberg JI; Reich K; Warren RB; Staumont-Sallé D; Girolomoni G; Papp K; de Bruin-Weller M; Thyssen JP; Zachariae R; Olsen CK; Wollenberg A
Br J Dermatol; 2022 Dec; 187(6):888-899. PubMed ID: 36082590
[TBL] [Abstract][Full Text] [Related]
66. Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.
Paller AS; Siegfried EC; Cork MJ; Wollenberg A; Arkwright PD; Gonzalez ME; Lockshin B; Chen Z; Bansal A; Levit NA; Prescilla R
Paediatr Drugs; 2023 Jan; 25(1):67-77. PubMed ID: 36529811
[TBL] [Abstract][Full Text] [Related]
67. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H;
N Engl J Med; 2021 Mar; 384(12):1101-1112. PubMed ID: 33761207
[TBL] [Abstract][Full Text] [Related]
68. Pharmacokinetics, pharmacodynamics, and exposure-efficacy of dupilumab in adults with atopic dermatitis.
Kamal MA; Davis JD; Kovalenko P; Srinivasan K; Simpson EL; Nakahara T; Sugaya M; Igarashi A; Ardeleanu M; Xu C; Arima K
Clin Transl Sci; 2022 Oct; 15(10):2342-2354. PubMed ID: 35986664
[TBL] [Abstract][Full Text] [Related]
69. The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis.
Kamal MA; Kovalenko P; Kosloski MP; Srinivasan K; Zhang Y; Rajadhyaksha M; Lai CH; Kanamaluru V; Xu C; Sun X; Simpson EL; Paller AS; Siegfried EC; Shumel B; Bansal A; Al-Huniti N; Davis JD
Clin Pharmacol Ther; 2021 Nov; 110(5):1318-1328. PubMed ID: 34270797
[TBL] [Abstract][Full Text] [Related]
70. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma.
Busse WW; Maspero JF; Rabe KF; Papi A; Wenzel SE; Ford LB; Pavord ID; Zhang B; Staudinger H; Pirozzi G; Amin N; Akinlade B; Eckert L; Chao J; Graham NMH; Teper A
Adv Ther; 2018 May; 35(5):737-748. PubMed ID: 29725983
[TBL] [Abstract][Full Text] [Related]
71. Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.
Silverberg JI; Thyssen JP; Simpson EL; Yosipovitch G; Ständer S; Valdez H; Rojo R; Biswas P; Myers DE; Feeney C; DiBonaventura M
Am J Clin Dermatol; 2021 Jul; 22(4):541-554. PubMed ID: 33954933
[TBL] [Abstract][Full Text] [Related]
72. Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial.
Cork MJ; Lockshin B; Pinter A; Chen Z; Shumel B; Prescilla R
Acta Derm Venereol; 2024 Feb; 104():adv13467. PubMed ID: 38348724
[TBL] [Abstract][Full Text] [Related]
73. Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials.
Fleming P; Drucker AM
J Am Acad Dermatol; 2018 Jan; 78(1):62-69.e1. PubMed ID: 28987493
[TBL] [Abstract][Full Text] [Related]
74. Dupilumab Treatment Reduces Hospitalizations in Adults With Moderate-to-Severe Atopic Dermatitis.
Silverberg JI; Rubini NPM; Pires MC; Rossi AB; Zhang A; Chen Z; Levit NA; Chao J; Shumel B; Bégo-Le Bagousse G
J Allergy Clin Immunol Pract; 2022 May; 10(5):1279-1285.e1. PubMed ID: 35032695
[TBL] [Abstract][Full Text] [Related]
75. Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis.
Yosipovitch G; de Bruin-Weller M; Armstrong A; Wu JJ; Herranz P; Thaçi D; Delevry D; Bagousse GB; Zhang R; Shumel B; Rossi AB; Chao J
Dermatol Ther (Heidelb); 2021 Dec; 11(6):2147-2157. PubMed ID: 34714527
[TBL] [Abstract][Full Text] [Related]
76. Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study.
Uchida H; Kamata M; Mizukawa I; Watanabe A; Agematsu A; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
Br J Dermatol; 2019 Nov; 181(5):1083-1085. PubMed ID: 31127860
[No Abstract] [Full Text] [Related]
77. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
Treister AD; Kraff-Cooper C; Lio PA
JAMA Dermatol; 2018 Oct; 154(10):1208-1211. PubMed ID: 30167653
[TBL] [Abstract][Full Text] [Related]
78. Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trials.
de Bruin-Weller M; Simpson EL; Cork M; Chen Z; Msihid J; Taniou C; Eckert L; Gadkari A; Bégo-Le Bagousse G
J Am Acad Dermatol; 2020 Nov; 83(5):1499-1501. PubMed ID: 32504724
[No Abstract] [Full Text] [Related]
79. Treatment With Dupilumab in Patients With Atopic Dermatitis: Systematic Review and Meta-Analysis.
Koskeridis F; Evangelou E; Ntzani EE; Kostikas K; Tsabouri S
J Cutan Med Surg; 2022; 26(6):613-621. PubMed ID: 36214355
[TBL] [Abstract][Full Text] [Related]
80. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Paller AS; Simpson EL; Siegfried EC; Cork MJ; Wollenberg A; Arkwright PD; Soong W; Gonzalez ME; Schneider LC; Sidbury R; Lockshin B; Meltzer S; Wang Z; Mannent LP; Amin N; Sun Y; Laws E; Akinlade B; Dillon M; Kosloski MP; Kamal MA; Dubost-Brama A; Patel N; Weinreich DM; Yancopoulos GD; O'Malley JT; Bansal A;
Lancet; 2022 Sep; 400(10356):908-919. PubMed ID: 36116481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
